Hikma delivers strong H1 performance and upgrades Group guidance
Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports…More
Tagged: Hikma
Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic® into the Saudi, Jordanian and Iraqi Markets
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced that it has recently signed an…More
Hikma and Guardant Health sign exclusive partnership agreement to bring transformative cancer diagnostic technology to the Middle East and North Africa
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive agreement with Guardant…More
Hikma continues strong momentum across the Group and upgrades guidance for 2023
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides…More
Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa
London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an…More
Hikma and Rakuten Medical sign exclusive licensing agreement for AlluminoxTM platform cancer treatment for the Middle East and North Africa
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive…More
Hikma delivers strong H1 performance and raises Generics guidance Growth in all three businesses and across all geographies
Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, report its interim results for the…More
Good momentum across all businesses and updated Generics guidance
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides…More
Riad Mishlawi named Chief Executive Officer of Hikma Pharmaceuticals PLC
Amman,Jordan — Hikma Pharmaceuticals PLC (Hikma, Group), announces that Riad Mishlawi, President of the Group’s…More
Hikma delivers a resilient underlying performance in 2022
Amman, Jordan — Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports…More
Hikma and Celltrion Healthcare sign new exclusive licensing agreement for Vegzelma® for the Middle East and North Africa region
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive…More
Hikma Pharmaceuticals and Celltrion Healthcare signed agreement for ustekinumab for the Middle East and North Africa region
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive licensing agreements with Celltrion…More